Novartis (NYSE: NVS) announced that Cosentyx (secukinumab) received U.S. FDA approval for treating pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor approved for this population. The approval, supported by well-controlled adult studies, pharmacokinetic modeling, and pediatric data from other indications, enables weight-based dosing that provides similar exposure to adult HS patients. The expansion reinforces Cosentyx’s dominant IL-17A franchise across dermatology and rheumatology indications in both adult and pediatric populations.
EMA pediatric indication filing; harmonized label with U.S.
Younger Pediatric Study
2026-2028
Potential <12 years HS development; psoriasis experience supports feasibility
Combination Studies
Ongoing
Cosentyx + antibiotics or hormonal therapy in refractory HS
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch performance, global regulatory expansion, and competitive positioning for Cosentyx in pediatric hidradenitis suppurativa. Actual results may differ due to physician adoption rates, pricing negotiations, and competitive dynamics with TNF inhibitors.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
